Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Open pharmacokinetic study with 5 parallel groups and two treatment phases (bemiparin 3,500
IU multiple dose and bemiparin 115 IU/kg single dose). The bemiparin pharmacokinetic profile
will be assessed by measuring its effects on the coagulation cascade. Plasma anti-Xa activity
(measured using chromogenic amidolytic assay) in IU per milliliter will be the primary
endpoint to assess the pharmacokinetic profile of bemiparin.